Combination HTNV and PUUV DNA Vaccine
NCT03718130
Unknown
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/16/2022
Locations: University of Maryland, College Park, College Park, Maryland
Conditions: Hantaan Virus Disease, Puumala Virus
Register for Updates
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
NCT04544267
Suspended
The primary objective of the study is to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type. The secondary objectives of the study are: * To compare QIV-HD to QIV-SD: * in participants 6 months through 35 months of age for the prevention of laboratory-confirmed... Read More
Gender:
ALL
Ages:
Between 6 months and 35 months
Trial Updated:
05/03/2022
Locations: Investigational Site Number :8400008, San Diego, California +9 locations
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
NCT02915016
Completed
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/27/2022
Locations: Alabama CRS, Birmingham, Alabama +16 locations
Conditions: HIV Infections
Register for Updates
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
NCT04142086
Completed
The primary objectives of the study are: * To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX® within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit * To describe the antibody responses elicited by each of the 3 dosages of vYF and by YF-VAX on Day 0 pre-vaccination and then on Day 10, Day 14, Day 28 and 6 months (Day 180) post-vaccination overall and by baseline flavivirus serostatus * To quantify the detectable yellow fever (YF) v... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/22/2022
Locations: Investigational Site Number 8400001, Silver Spring, Maryland
Conditions: Yellow Fever (Healthy Volunteers)
Register for Updates
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362
Completed
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Pr... Read More
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/21/2022
Locations: Not set, Madison, Wisconsin +1 locations
Conditions: Pertussis
Register for Updates
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
NCT03630809
Terminated
The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines. There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence. This study will use a Dendritic C... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Breast Cancer, HER2-positive Breast Cancer, HER-2 Gene Amplification, HER2 Positive Breast Carcinoma, HER-2 Protein Overexpression, Breast Cancer, Male, Breast Cancer Female
Register for Updates
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
NCT03560258
Completed
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who were on antiretroviral therapy (ART). The study aimed to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2022
Locations: Alabama CRS, Birmingham, Alabama +14 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
NCT03409276
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/28/2022
Locations: Alabama CRS, Birmingham, Alabama +5 locations
Conditions: HIV Infections
Register for Updates
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
NCT02842853
Completed
The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra®, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US). Primary Objectives: * To demonstrate the immune lot consistency of the antibody responses to meningococc... Read More
Gender:
ALL
Ages:
Between 10 years and 55 years
Trial Updated:
03/24/2022
Locations: Not set, Birmingham, Alabama +88 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
NCT02842866
Completed
The aim of the study was to demonstrate non-inferiority of immunogenicity and evaluate the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid conjugate vaccine (MenACYW conjugate vaccine) compared to a single dose of Meningococcal Polysaccharide Vaccine Serogroups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in adults 56 years of age and older in the United States. Primary objective: -To demonstrate the non-inferiority of the vaccine ser... Read More
Gender:
ALL
Ages:
56 years and above
Trial Updated:
03/24/2022
Locations: Not set, Chandler, Arizona +35 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
NCT03282240
Completed
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational high-dose trivalent influenza vaccine (TIV-HD) in adults.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/24/2022
Locations: Sanofi Pasteur Investigational Site 037, Anaheim, California +35 locations
Conditions: Influenza
Register for Updates
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
NCT02199691
Completed
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/24/2022
Locations: Not set, Birmingham, Alabama +35 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates